Australia's Dimerix climbs on India nod to test drug in COVID-19 patients

Dimerix

24/09/2021 01:42

** Shares of drug developer  DXB.AX  rise as much as 8.9% to
A$0.305, their biggest intraday pct gain since Aug. 23
    ** Co says Indian regulator has recommended a clinical study
of DMX-200 in COVID-19 patients (https://bit.ly/3lQLU48)
    ** The drug, primarily used to treat hypertension and kidney
disease, will now be tested for treating respiratory
complications associated with COVID-19  
    ** Multiple sites have been decided upon in India to begin
recruitment for the clinical study to assess DMX-200 in COVID-19
patients - DXB
    ** Co set to gain 7.1% for the week, its best one since
Sept. 3
    ** Stock has risen 19.2% this year, as of last close

 (Reporting by Yamini C S)
 ((Yamini.CS@thomsonreuters.com;))